Atossa Genetics is a clinical-stage biopharmaceutical company developing (Z)-endoxifen, an oral selective estrogen receptor modulator and degrader, for the treatment of breast cancer and rare diseases including Duchenne muscular dystrophy, female DMD carrier disease, and McCune-Albright Syndrome. The company's lead program focuses on multiple Phase 2 oncology trials evaluating (Z)-endoxifen for reducing breast density in premenopausal women, treating early-stage estrogen receptor-positive breast cancer, managing ductal carcinoma in situ, and treating metastatic breast cancer in combination with other therapies. Atossa is pre-revenue and generates no current income; the company operates through research and development activities and outsourced manufacturing and clinical operations, with the path to revenue depending on successful drug development, regulatory approval, and eventual commercialization across its cancer and rare disease indications.
| USD millions | FY2025 |
|---|---|
| Net Income | -35 |